Movement Alert｜TG Therapeutics Falls 5.37% in Pre-Market Trading, Q2 EPS Misses Estimates by 85%

Market Focus08-03

On August 3, TG Therapeutics fell 5.37% in pre-market trading, trading at $49.5/share, with turnover of $766,700. The decline was triggered by the company's Q2 earnings report, which showed EPS of $0.05 versus analyst consensus estimates of $0.31-$0.33, missing expectations by approximately 85%.

The reported EPS also represents a 70.59% decrease from $0.17 per share in the same quarter last year. Notably, this marks the third consecutive quarter in which the company has significantly missed earnings expectations, intensifying market concerns over its profitability trajectory. However, Q2 revenue of $240.335 million did beat the $229.721 million estimate, suggesting commercial momentum for its core product BRIUMVI remains intact.

TG Therapeutics is a commercial-stage biopharmaceutical company focused on novel treatments for B-cell mediated diseases. Its flagship product BRIUMVI (Ublituximab), an anti-CD20 monoclonal antibody approved in the US, EU, and UK for relapsing forms of multiple sclerosis, continues to be the primary revenue driver.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130685576?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130685576","market":"us","top_or_hot":-1,"title":"Movement Alert｜TG Therapeutics Falls 5.37% in Pre-Market Trading, Q2 EPS Misses Estimates by 85%","media":"Market Focus","content":"<p><p>On August 3, TG Therapeutics fell 5.37% in pre-market trading, trading at $49.5/share, with turnover of $766,700. The decline was triggered by the company's Q2 earnings report, which showed EPS of $0.05 versus analyst consensus estimates of $0.31-$0.33, missing expectations by approximately 85%.</p><p>The reported EPS also represents a 70.59% decrease from $0.17 per share in the same quarter last year. Notably, this marks the third consecutive quarter in which the company has significantly missed earnings expectations, intensifying market concerns over its profitability trajectory. However, Q2 revenue of $240.335 million did beat the $229.721 million estimate, suggesting commercial momentum for its core product BRIUMVI remains intact.</p><p>TG Therapeutics is a commercial-stage biopharmaceutical company focused on novel treatments for B-cell mediated diseases. Its flagship product BRIUMVI (Ublituximab), an anti-CD20 monoclonal antibody approved in the US, EU, and UK for relapsing forms of multiple sclerosis, continues to be the primary revenue driver.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜TG Therapeutics Falls 5.37% in Pre-Market Trading, Q2 EPS Misses Estimates by 85%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜TG Therapeutics Falls 5.37% in Pre-Market Trading, Q2 EPS Misses Estimates by 85%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-03 19:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 3, TG Therapeutics fell 5.37% in pre-market trading, trading at $49.5/share, with turnover of $766,700. The decline was triggered by the company's Q2 earnings report, which showed EPS of $0.05 versus analyst consensus estimates of $0.31-$0.33, missing expectations by approximately 85%.</p><p>The reported EPS also represents a 70.59% decrease from $0.17 per share in the same quarter last year. Notably, this marks the third consecutive quarter in which the company has significantly missed earnings expectations, intensifying market concerns over its profitability trajectory. However, Q2 revenue of $240.335 million did beat the $229.721 million estimate, suggesting commercial momentum for its core product BRIUMVI remains intact.</p><p>TG Therapeutics is a commercial-stage biopharmaceutical company focused on novel treatments for B-cell mediated diseases. Its flagship product BRIUMVI (Ublituximab), an anti-CD20 monoclonal antibody approved in the US, EU, and UK for relapsing forms of multiple sclerosis, continues to be the primary revenue driver.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1130685576","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130685576","pubTimestamp":1785756332,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 3, TG Therapeutics fell 5.37% in pre-market trading, trading at $49.5/share, with turnover of $766,700. The decline was triggered by the company's Q2 earnings report, which showed EPS of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"走势提醒|TG Therapeutics 盘前交易下跌 5.37%，第二季度每股收益低于预期 85%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"On August 3, TG Therapeutics fell 5.37% in pre-market trading, trading at $49.5/share, with turnover of $766,700. The decline was triggered by the company's Q2 earnings report, which showed EPS of $0.05 versus analyst consensus estimates of $0.31-$0.33, missing expectations by approximately 85%.The reported EPS also represents a 70.59% decrease from $0.17 per share in the same quarter last year. Notably, this marks the third consecutive quarter in which the company has significantly missed earnings expectations, intensifying market concerns over its profitability trajectory. However, Q2 revenue of $240.335 million did beat the $229.721 million estimate, suggesting commercial momentum for its core product BRIUMVI remains intact.TG Therapeutics is a commercial-stage biopharmaceutical company focused on novel treatments for B-cell mediated diseases. Its flagship product BRIUMVI (Ublituximab), an anti-CD20 monoclonal antibody approved in the US, EU, and UK for relapsing forms of multiple sclerosis, continues to be the primary revenue driver.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130685576","isCrawlerRequest":true}